Q4: 2026-02-25 Earnings Summary
EPS of -$1.15 beats by $0.07
| Revenue of $203.00M (-10.57% Y/Y) beats by $46.87M
Ionis Pharmaceuticals, Inc. (IONS) TD Cowen 46th Annual Health Care Conference March 2, 2026 10:30 AM EST
Company Participants
Brett Monia – Founder, CEO & Director
Conference Call Participants
Yaron Werber – TD Cowen, Research Division
Presentation
Yaron Werber
TD Cowen, Research Division
Good morning, everybody, and thank you for joining us for the 46th Annual TD Cowen Healthcare Conference. I’m Yaron Werber from the biotech team, and it’s really a great pleasure to moderate the next fireside chat with Brett Monia, Chief Executive Officer of Ionis. Brett, good to see you.
Brett Monia
Founder, CEO & Director
Good to see you. Yaron, I forgot how cold it gets in Boston.
Yaron Werber
TD Cowen, Research Division
It’s about to get to 60, I believe, in a few days, but we avoided the snowstorm, which is what we were worried about. Next year, we’ll do it in San Diego.
Brett Monia
Founder, CEO & Director
Yes. Sounds great…
Question-and-Answer Session
Yaron Werber
TD Cowen, Research Division
So lots to talk about. Last year was really, I would say, a breakout year for Ionis. You are a topic for this year. So we’re actually thinking this is going to be the breakout year since there’s so much going on with almost 5 sets of data coming by the end of this year. So maybe let me turn it over to you, maybe as you think about the business, what are the critical deliverables for you and things that you’re mostly focused on?
Brett Monia
Founder, CEO & Director
Thanks, Yaron. Good morning, everybody. Thanks for being here. So indeed, 2026 is set up to be a really big year for Ionis with so many pipeline and commercial events coming. And of course, what makes this year so transformational for Ionis and there’s so much opportunity to get involved with Ionis this
